Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Bispecific Antibodies: A Smart Arsenal for Cancer Immunotherapies
Gihoon You, Jonghwa Won, Yangsoon Lee, et al.
Vaccines (2021) Vol. 9, Iss. 7, pp. 724-724
Open Access | Times Cited: 37

Showing 1-25 of 37 citing articles:

Drugging p53 in cancer: one protein, many targets
Ori Hassin, Moshe Oren
Nature Reviews Drug Discovery (2022) Vol. 22, Iss. 2, pp. 127-144
Open Access | Times Cited: 381
The Dawn of a New Era: Targeting the “Undruggables” with Antibody-Based Therapeutics
Linghui Qian, Xuefen Lin, Xue Gao, et al.
Chemical Reviews (2023) Vol. 123, Iss. 12, pp. 7782-7853
Closed Access | Times Cited: 64
The emerging landscape of novel 4-1BB (CD137) agonistic drugs for cancer immunotherapy
Christina Claus, Claudia Ferrara, Christian Klein
mAbs (2023) Vol. 15, Iss. 1
Open Access | Times Cited: 54
Cell fate regulation governed by p53: Friends or reversible foes in cancer therapy
Bin Song, Ping Yang, Shuyu Zhang
Cancer Communications (2024) Vol. 44, Iss. 3, pp. 297-360
Open Access | Times Cited: 22
A review on targeting tumor microenvironment: The main paradigm shift in the mAb-based immunotherapy of solid tumors
Ayuob Aghanejad, Samad Farashi Bonab, Maryam Sepehri, et al.
International Journal of Biological Macromolecules (2022) Vol. 207, pp. 592-610
Closed Access | Times Cited: 58
Metal-organic frameworks (MOFs) as biomolecules drug delivery systems for anticancer purposes
Michele Coluccia, Valeria Parisse, Paolo Guglielmi, et al.
European Journal of Medicinal Chemistry (2022) Vol. 244, pp. 114801-114801
Closed Access | Times Cited: 54
Immunogenicity assessment of bispecific antibody-based immunotherapy in oncology
Yanchen Zhou, Hweixian Leong Penny, Mark A. Kroenke, et al.
Journal for ImmunoTherapy of Cancer (2022) Vol. 10, Iss. 4, pp. e004225-e004225
Open Access | Times Cited: 47
Emerging targeted protein degradation tools for innovative drug discovery: From classical PROTACs to the novel and beyond
Yue Zhong, Fanglian Chi, Hanyu Wu, et al.
European Journal of Medicinal Chemistry (2022) Vol. 231, pp. 114142-114142
Closed Access | Times Cited: 39
Strategies for clinical dose optimization of T cell-engaging therapies in oncology
Kathryn Ball, Simon J. Dovedi, Pavan Vajjah, et al.
mAbs (2023) Vol. 15, Iss. 1
Open Access | Times Cited: 38
Reigniting hope in cancer treatment: the promise and pitfalls of IL-2 and IL-2R targeting strategies
Shan Muhammad, Tao Fan, Yang Hai, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 38
Bridging the gap between tumor-on-chip and clinics: a systematic review of 15 years of studies
Charlotte Bouquerel, Anastasiia Dubrova, Isabella Hofer, et al.
Lab on a Chip (2023) Vol. 23, Iss. 18, pp. 3906-3935
Open Access | Times Cited: 15
Efficacy and safety of bispecific antibodies vs. immune checkpoint blockade combination therapy in cancer: a real-world comparison
Linyan Cheng, Lujun Chen, Yuan Shi, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 5
Bispecific antibodies and CLEM: an analytical approach to advanced cell imaging for therapeutic strategies
Han‐ul Kim, Young Kwan Kim
Han-guk hyeonmigyeong hakoeji/Applied microscopy (2025) Vol. 55, Iss. 1
Open Access
Gene Editing in ErbB/HER Family-Mediated Cancer Immunology
Ling Yin
IntechOpen eBooks (2025)
Closed Access
Development of Bispecific Antibody for Cancer Immunotherapy: Focus on T Cell Engaging Antibody
Dain Moon, Nara Tae, Yunji Park, et al.
Immune Network (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 23
HER2-Low Breast Cancer: Where Are We?
Chiara Molinelli, Flavia Jacobs, Caterina Marchiò, et al.
Breast Care (2022) Vol. 17, Iss. 6, pp. 533-545
Open Access | Times Cited: 23
Self-Assembly of Epitope-Tagged Proteins and Antibodies for Delivering Biologics to Antigen Presenting Cells
Shuai Gong, Jingyi Qiu, S. Thayumanavan
Journal of the American Chemical Society (2023) Vol. 146, Iss. 1, pp. 33-38
Closed Access | Times Cited: 10
Expanding horizons in cancer therapy by immunoconjugates targeting tumor microenvironments
Amir Fattahi, Mahboobeh Jafari, Ghazal Farahavar, et al.
Critical Reviews in Oncology/Hematology (2024) Vol. 201, pp. 104437-104437
Closed Access | Times Cited: 3
Insights on recent innovations in bladder cancer immunotherapy
Mohamed Abd El-Salam, Claire E.P. Smith, Chong-xian Pan
Cancer Cytopathology (2022) Vol. 130, Iss. 9, pp. 667-683
Closed Access | Times Cited: 16
Bispecific Antibody-Based Immune-Cell Engagers and Their Emerging Therapeutic Targets in Cancer Immunotherapy
Ha Gyeong Shin, Ha Rim Yang, Aerin Yoon, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 10, pp. 5686-5686
Open Access | Times Cited: 14
The manufacturing considerations of bispecific antibodies
Dennis Underwood, Jeffrey Bettencourt, Zahra Jawad
Expert Opinion on Biological Therapy (2022) Vol. 22, Iss. 8, pp. 1043-1065
Closed Access | Times Cited: 14
Combining of Oncolytic Virotherapy and Other Immunotherapeutic Approaches in Cancer: A Powerful Functionalization Tactic
Hai Zou, Xiaozhou Mou, Biao Zhu
Global Challenges (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 13
Drug Repurposing to Enhance Antitumor Response to PD-1/PD-L1 Immune Checkpoint Inhibitors
Xavier Thuru, Romain Magnez, Hassiba El-Bouazzati, et al.
Cancers (2022) Vol. 14, Iss. 14, pp. 3368-3368
Open Access | Times Cited: 11
In Vivo Electroporation of Plasmid DNA: A Promising Strategy for Rapid, Inexpensive, and Flexible Delivery of Anti-Viral Monoclonal Antibodies
Silvère Pagant, Rachel A. Liberatore
Pharmaceutics (2021) Vol. 13, Iss. 11, pp. 1882-1882
Open Access | Times Cited: 14
Longitudinal evaluation of the biodistribution and cellular internalization of the bispecific CD3xTRP1 antibody in syngeneic mouse tumor models
Gerwin W. Sandker, Jim Middelburg, Evienne Wilbrink, et al.
Journal for ImmunoTherapy of Cancer (2023) Vol. 11, Iss. 10, pp. e007596-e007596
Open Access | Times Cited: 5
Page 1 - Next Page

Scroll to top